AMA 2023 Overdose Report IQVIA Data Buprenorphine

Added 11/8/23

Total dispensed prescriptions to treat opioid use disorder (2012-2021)

From 2012 to 2021, medications to treat opioid use disorder (MOUD) increased 104%; from 2020 to 2021, however, it only increased 1.6%.

AMA issue brief: The Nation’s Drug Overdose Epidemic: Considerations for Employers

This AMA issue brief provides key facts and steps employers can take to help end the nation's drug overdose epidemic.

Issue brief: AMA, Colorado physicians, Manatt Health Pain Care Actuarial Analysis

This issue brief summarizes the findings of a recent AMA, Colorado Medical Society, Colorado Pain Society and Manatt Health report submitted to the Colorado Division of Insurance in support of multidisciplinary, multimodal pain care.

Buprenorphine Maintenance vs. Methadone Maintenance or Placebo for Opioid Use Disorder

Putting Evidence Into Practice: Buprenorphine Maintenance vs. Methadone Maintenance or Placebo for Opioid Use Disorder. Elizabeth Salisbury-Afshar, MD, MPH, Heartland Health Outreach, Chicago, Illinois. Am Fam Physician. 2015 Feb 1;91(3):165-166.

American Society of Anesthesiologists’ resources on pain management and anesthesia

Learn more about anesthesia, pain management and the medical experts committed to patient safety and high-quality care.

Enhanced Attestation of Mental Health and Substance Use Disorder Parity

Use of this form by state regulators--and health insurers--can help ensure meaningful state oversight and compliance with the federal Mental Health Parity and Addiction Equity Act. This guides health insurers through the necessary analysis to demonstrate compliance with the law, which can then be made available to a state department of insurance to streamline regulatory review.

AMA Education Hub: Opioid and Pain Management: Guidelines, Research and Treatments

Fulfill your state-mandated CME credits while enhancing your knowledge of opioid and non-opioid pain management, safe opioid prescribing and substance use treatment. Learn now. CME 44.25 Total Credits

What does a sufficient pain care formulary look like?

The AMA believes it is essential for formularies to also include a broad range of evidence-based pain care options. This resource is meant to provide an overview for policymakers of the types of treatments practicing physicians use to treat pain but may be subject to formulary exclusion or administrative barriers such as prior authorization or step therapy, or subject to cost-prohibitive co-pays, cost sharing and adverse formulary tiering.

The AMA Urges Removing All Barriers to Treatment for Substance Use Disorder

Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System

JAMA Psychiatry Traci C. Green, PhD, MSc; Jennifer Clarke, MD; Lauren Brinkley-Rubinstein, PhD; Brandon D. L. Marshall, PhD; Nicole Alexander-Scott, MD, MPH; Rebecca Boss, MA; Josiah D. Rich, MD, MPH

Why It’s Inappropriate Not to Treat Incarcerated Patients with Opioid Agonist Therapy

AMA Journal of Ethics. September 2017, Volume 19, Number 9: 922-930. Sarah E. Wakeman, MD

AMA Substance Use and Pain Care Task Force

The AMA Substance Use and Pain Care Task Force urges physicians and other health care professions to continue taking action to help reverse the nation’s drug overdose epidemic—and the Task Force also calls on policymakers to take specific steps to remove barriers to evidence-based care for patients with pain and those with a substance use disorder.

Learn More

Be part of the solution.

Join the AMA today and help us lead the effort
to reverse the nation’s opioid epidemic.